ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 61 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104 | +60.0% | 9,126 | +44.3% | 0.00% | – |
| Q2 2023 | $65 | -30.1% | 6,325 | -47.6% | 0.00% | – |
| Q1 2023 | $93 | +106.7% | 12,079 | +98.7% | 0.00% | – |
| Q4 2022 | $45 | -99.1% | 6,080 | +818.4% | 0.00% | – |
| Q3 2022 | $5,000 | -28.6% | 662 | -15.5% | 0.00% | – |
| Q2 2022 | $7,000 | -58.8% | 783 | -58.5% | 0.00% | – |
| Q1 2022 | $17,000 | -95.7% | 1,886 | -93.3% | 0.00% | – |
| Q4 2021 | $392,000 | +668.6% | 28,196 | +494.0% | 0.00% | – |
| Q3 2021 | $51,000 | +292.3% | 4,747 | +223.1% | 0.00% | – |
| Q2 2021 | $13,000 | -91.3% | 1,469 | -89.6% | 0.00% | – |
| Q1 2021 | $150,000 | +500.0% | 14,105 | +405.0% | 0.00% | – |
| Q3 2020 | $25,000 | – | 2,793 | +139550.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 2 | -98.5% | 0.00% | – |
| Q1 2018 | $1,000 | – | 134 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 2,571,450 | $23,143,000 | 2.13% |
| Omega Fund Management, LLC | 1,284,900 | $11,564,000 | 1.31% |
| Avidity Partners Management LP | 1,495,000 | $13,455,000 | 0.36% |
| Samsara BioCapital, LLC | 275,169 | $2,477,000 | 0.31% |
| Orbimed Advisors | 3,070,955 | $27,639,000 | 0.28% |
| Ikarian Capital, LLC | 300,454 | $2,704,000 | 0.22% |
| TIGER MANAGEMENT L.L.C. | 137,728 | $1,240,000 | 0.22% |
| DAFNA Capital Management LLC | 113,302 | $1,020,000 | 0.21% |
| EcoR1 Capital, LLC | 522,635 | $4,704,000 | 0.18% |
| Artal Group S.A. | 593,030 | $5,337,000 | 0.11% |